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Abstract: Oropharyngeal candidiasis is a very common localized infection of the mucus 
membranes of the oropharynx that is most commonly caused by the patient’s own commensal 
Candida albicans. It is the most common opportunistic infection affecting patients with the 
human immunodeficiency virus (HIV) and is also quite common in patients with hematological 
malignancies. Effective treatment options are of high importance given the worldwide incidence 
of these disease states and the potential for development of oropharyngeal candidiasis in these 
patients. Various systemic and topical treatment options for patients with oropharyngeal can-
didiasis have existed for many years. Miconazole buccal tablets have recently been approved 
by the US Food and Drug Administration for the treatment of oropharyngeal candidiasis. 
Clinical trials have demonstrated noninferiority in the treatment of oropharyngeal candidiasis 
when compared with clotrimazole troches in patients with HIV and against miconazole gel in 
patients with head and neck cancer. Miconazole buccal tablets exhibit few drug interactions 
because of low systemic absorption and are generally well tolerated with a safety profile similar 
to comparators. The once-daily dosing schedule may improve patient adherence compared with 
topical alternatives; however, the cost of therapy may be a barrier for some patients and should 
be considered by prescribers compared with alternative treatments.
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Introduction
Oropharyngeal candidiasis (OPC) is a very common localized infection of the mucus 
membranes of the oropharynx caused by Candida species. Most commonly, it is 
caused by the patient’s own commensal Candida albicans, but it may also be caused 
by other Candida species such as C. glabrata, C. tropicalis, and C. krusei.1 There are 
several clinical variants of OPC. Type one OPC, or pseudomembranous OPC, is also 
known as “thrush”. Thrush is characterized by white curd-like discrete plaques on an 
erythematous base found on the buccal mucosa, throat, tongue, or gingivae. These 
plaques rub off and reveal a tender red surface underneath. Type two OPC is the ery-
thematous variant. In erythematous OPC there are smooth red patches on the hard or 
soft palate, dorsum of tongue, or buccal mucosa. Denture-induced stomatitis may also 
be considered a variant of erythematous OPC and is seen in 65% of denture wearers, 
presenting as either a smooth or granular erythema confined to the denture-bearing 
area of the hard palate.2 The third OPC type is the hyperplastic variant. This consists 
of white, firmly adherent patches on the bilateral buccal mucosa, tongue, or palate. 
Finally, angular cheilitis, which is a red fissured lesion at the corners of the mouth, 





Symptoms include mouth irritation and a burning sensation 
on the tongue. It may also cause perturbations of taste and 
ability to eat and/or speak.
OPC is the most common opportunistic fungal infection 
among patients infected with human immunodeficiency virus 
(HIV).4 OPC also affects patients with cancer. A systematic 
review of oral fungal infections in patients receiving cancer 
treatment found a weighted prevalence of 39.1% for patients 
undergoing cancer treatment.5 However, unlike esophageal 
candidiasis, which is only seen in the setting of major 
derangements of cell-mediated immunity such as AIDS, 
immunosuppression for transplantation or chemotherapy, 
OPC is also associated with very small derangements in the 
host’s local immune response, such as that seen with the 
use of topical or systemic antibacterial therapy, inhaled or 
systemic steroids, and diabetes.
A variety of options exist for the treatment of OPC. 
This article focuses on one of the newest additions to our 
antifungal armamentarium, miconazole buccal tablets 
(Oravig™, Strativa Pharmaceutics, Woodcliff Lake, NJ). 
The FDA licensure of Oravig (miconazole) for the treat-
ment of oropharyngeal candidiasis occurred in April 
2010, with the majority of clinical evidence considered 
for FDA approval coming from observations and trials in 
humans conducted between 2000 and 2004.6 Miconazole 
buccal tablets are currently the only oral preparation of 
miconazole licensed in the USA for treatment of oropha-
ryngeal candidiasis. Outside the USA, miconazole oral gel 
(MOG), marketed under the trade name Daktarin™ (Janssen 
Pharmaceutica, Beerse, Belgium), has been available for 
the treatment of oral and gastrointestinal fungal infections 
since 1977. The European Union also recently approved 
oral miconazole buccal tablets (Loramyc™, BioAlliance 
Pharma, Paris, France) for the treatment of oropharyngeal 
candidiasis in immune-compromised patients in 2007. 
Miconazole buccal tablet safety data exists only for per-
sons over the age of 16 years, while use of MOG extends 
to those greater than 4 months. MOG and other antifungal 
preparations are mentioned here because trials comparing 
these have factored into the decision for licensing and use 
in the USA.
Mechanism of action
Miconazole is a broad-spectrum triazole antifungal available 
in the USA since the 1970s.
Miconazole works at the cell membrane level by limit-
ing ergosterol synthesis through inhibiting the cytochrome 
P450 14α-demethylase enzyme. Miconazole also affects 
the   synthesis of triglycerides and fatty acids and inhibits 
  oxidative and peroxidative enzymes.7
Miconazole, like other triazole antifungals, has long 
exhibited in vitro activity against Candida species, including 
C. albicans, C. glabrata, and C. krusei; however, miconazole 
resistance has been reported in up to 17% of C. albicans and 
45% in non-albicans species.8 The mechanism of resistance 
is thought to be due to mutations in the EFG11 gene, expres-
sions of transporter proteins functioning as efflux pumps 
coded by CDR1 and CDR2 genes, or to major facilitator 
genes.9,10
A recent in vitro analysis studied miconazole suscep-
tibilities utilizing Clinical Laboratory and Susceptibility 
standards with current clinical isolates. Miconazole was 
shown to retain activity against most Candida species. The 
authors also reported that miconazole had a 12-fold lower 
minimum inhibitory concentration to inhibit the growth of 
90% of organisms (minimum inhibitory concentration [MIC] 
90) than fluconazole and exhibited activity against flucon-
azole resistant strains.11 Six Candida isolates, including two 
fluconazole resistant strains, were subsequently tested by the 
same authors for the development of resistance to micon-
azole. Two isolates experience an increase in MIC, though 
no isolate acquired resistance to miconazole.12 Despite this 
positive evidence, antimicrobial resistance concerns, includ-
ing miconazole, remain an important consideration when 
selecting treatments for OPC.
A pharmacokinetic study of 18 healthy volunteers showed 
a mean maximum salivary concentration of 15 mcg/mL at 
7 hours following placement of the tablet. An average saliva 
exposure to miconazole of 55.23 mcg. hours/mL was esti-
mated from the AUC (0–24 hours). The terminal half-life of 
miconazole buccal tablets is 24 hours.13
The systemic absorption of miconazole buccal tablets is 
limited. Plasma concentrations were below the lower limit 
of quantification (0.4 mcg/mL) in 157/162 (97%) samples 
from healthy volunteers following single-dose applica-
tion. Measurable plasma concentrations ranged from 0.5 to 
0.83 mcg/mL. Following 7 days of therapy in 40 HIV-positive 
patients, plasma concentrations of miconazole were below 
the detectable limit (0.1 mcg/mL). The manufacturer recom-
mends caution in patients with hepatic dysfunction, despite 
limited systemic absorption. Miconazole buccal tablets are 
excreted unchanged less than 1% in the kidneys. As such, 
renal dosing adjustments are not needed.7
Miconazole is an inhibitor of CYP3A4 and CYP2C9. 
Despite limited systemic absorption with the buccal tablet 
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with agents such as phenytoin, oral hypoglycemics and 
ergot alkaloids. Cases of bleeding and bruising have been 
reported following administration of oral miconazole in 
patients also taking warfarin. It is recommended to monitor 
closely for evidence of bleeding, prothrombin time, and 
international normalized ratio (INR) if a patient is taking 
both medications concominantly.7
Miconazole buccal tablets are contraindicated in patients 
with known hypersensitivity (eg, anaphylaxis) to miconazole, 
milk protein concentrate, or any other component of the 
  product. They are listed as a pregnancy category C medica-
tion and should be avoided unless the risk to the mother 
outweighs risk to the fetus. It is not known whether oral 
miconazole is excreted in breast milk and there have been 
no studies to date in patients under the age of 16.7
Dosing and patient instructions
Patients are instructed to apply the rounded side of the 
50 mg tablet to the upper gum region just above the right 
or left incisor following brushing of teeth in the morning. 
The tablet should be held in place until dissolved and should 
not be chewed, swallowed, or crushed. There are no restric-
tions on normal eating and drinking; however, the chewing 
of gum and wearing of upper dentures should be avoided. 
The average duration of adhesion was 15 hours in healthy 
volunteer trials. If the tablet falls off or does not adhere 
within 6 hours it is recommended the patient replace the 
tablet. It the tablet is swallowed within 6 hours, patients 
should drink a glass of water and apply a new tablet only 
once. If the tablet falls off or is swallowed after 6 hours the 
patient should wait until the next scheduled dose to apply 
a new tablet.7
Early clinical studies of safety  
and tolerability
Chaumont et al first examined safety and tolerability of novel 
slow-release miconazole buccal tablets in healthy individuals 
in 2001.14 Published before the manuscript of Cardot et al13 
containing specific pharmacokinetics data from the same 
subjects and study period, the Chaumont Phase I study com-
pared the 100 mg and the 50 mg miconazole buccal tablets, 
and miconazole oral gel (Daktarin). Eighteen subjects, ages 
18–35, received each of the three treatments (one 50 mg, 
one 100 mg, or three applications of gel over 8.5 hours) in 
random order, with each treatment followed by a 1-week 
washout period.13,14 No adverse events were recorded with 
the 50 mg miconazole buccal tablet; bad taste was described 
by one participant in relation to the 50 mg tablet (as opposed 
to 13 reports with gel use). Discomfort was reported with 
the 100 mg tablet, presumably secondary to tablet size and 
not localized chemical irritation.
Clinical studies and efficacy
Using a distinct miconazole buccal tablet size, Van Roey 
et al published a study in 2004 of 357 HIV-infected adults in 
Uganda who were randomized to receive either a once-daily 
10 mg slow-release miconazole buccal tablet or a 400 mg 
daily oral dose of ketoconazole for treatment of clinically 
diagnosed oropharyngeal candidiasis.15 Treatment was 
provided for 7 or 14 days, depending on response at day 7. 
The primary outcome studied was clinical cure, defined as a 
complete absence of symptoms and signs. Using per protocol 
analysis, the 10 mg tablet demonstrated noninferiority to 
systemic ketoconazole for oropharyngeal candidiasis, with 
reported cure rates at end of treatment of 93% (155/167) and 
96% (159/165), respectively. Microscopic examination for 
fungal elements was negative in a slightly greater proportion 
of ketoconazole than miconazole buccal tablet recipients 
(75% compared with 70%; baseline negative smear rate of 
23% in both groups) at end of treatment.
Two subsequent prospective randomized clinical trials 
involving the currently available 50 mg tablet size form the 
basis of efficacy and noninferiority data (as compared to 
alternative oral antifungal preparations) to date for use of 
miconazole buccal tablets. Bensadoun et al in 2002 evalu-
ated 282 adult patients receiving radiotherapy for head and 
neck cancer and oropharyngeal candidiasis (defined both by 
consistent clinical exam and positive fungal culture), who 
were randomly triaged to receive either once-daily 50 mg 
MBT or 125 mg miconazole gel applied four times daily 
for 14 days.16 Noninferiority (P , 0.0001) was established 
for the miconazole buccal tablet in a modified intent to treat 
analysis. The primary endpoint studied was treatment suc-
cess, which was defined by a complete or partial clinical 
response (independent of mycologic data). Comparatively, 
56% of the miconazole treated subjects and 48.9% of the gel 
users had achieved clinical success; symptomatic improve-
ment was also not statistically significant between the two 
groups (70.3% and 76.5% respectively).
The SMiLES (study of miconazole Lauriad® efficacy and 
safety) published in 2010, examined 578 adult HIV-infected 
patients (at multiple international sites) with clinical evidence 
of oropharyngeal candidiasis accompanied by positive KOH 
smears and fungal cultures, who were randomized to receive 
14 days of once-daily active 50 mg miconazole buccal tablets 





buccal tablets plus active 10 mg clotrimazole troches five 
times daily.17 The primary endpoint was clinical cure defined 
as complete resolution of signs and symptoms; additional 
data on the secondary endpoints of clinical success (clinical 
cure or improvement) and mycologic cure were included. 
Using an intent-to-treat analysis, 61% of miconazole-treated 
patients compared with 65% of clotrimazole-troche treated 
patients attained the primary endpoint of clinical cure. 
Mycologic cure (27% with miconazole tablets, 25% with 
clotrimazole), clinical success, and rates of relapse were not 
statistically significant between the two groups.
Adherence
In those treated with miconazole buccal tablets for oropha-
ryngeal candidiasis in the clinical context of radiotherapy 
for head and neck cancer, Bensadoun et al found that 6% of 
subjects were considered noncompliant (.3 missed doses); 
adherence in the comparison miconazole gel–treated subjects 
was incompletely assessed and not specifically reported.16 
Within the SMiLES trial, overall compliance with therapy 
was 87.2% for the miconazole buccal tablet group and 87.1% 
in the clotrimazole group.17 Adherence was determined by 
the number of unused tablets or troches returned at day 
14 (end of treatment) and through daily self-administered 
  questionnaires. A subset of 40 participants (20 from the 
miconazole tablet group and 20 from the clotrimazole group) 
underwent testing of miconazole levels at day 7, but systemic 
levels were undetectable (below the sensitivity of the assay) 
in all 40 subjects.
Adverse events
Bensadoun et al reported the number of adverse events 
was similar among users of miconazole buccal tablets and 
miconazole gel, leading to discontinuation of drug in 3/141 
and 6/141 study participants, respectively. Tolerability was 
assessed through a self-administered questionnaire, notably 
with 6.1% of miconazole tablet–treated patients reporting 
dysgeusia as opposed to 0% of gel-treated patients. Adverse 
events (diarrhea, headache, nausea and vomiting being 
the most frequent) in the SMiLES study were comparable 
between its study groups, with no statistically significant 
difference in overall rates for miconazole buccal tablet– or 
clotrimazole-treated participants. When collectively con-
sidered by expert reviewers, none of the serious adverse 
events (including death, anemia, lower respiratory tract 
infection) reported in trials have been directly attributed to 
oral miconazole buccal tablets.14 With any of the available 
local antifungal treatments for oropharyngeal candidiasis, 
listed side effects include nausea, diarrhea, headache and 
dysgeusia. Specific to the miconazole buccal tablets, local 
site reactions, such as oral discomfort (5%), burning (7.2%), 
bad taste (7.2%) and pain (1.8%), are reported but very infre-
quently lead to discontinuation of drug use.16,17
Potential drug interactions with miconazole (and the 
relevance of miconazole to inhibit CYP2C9 and CYP3A4) 
are discussed elsewhere, but it should be noted that liver func-
tion test (LFT) abnormalities were infrequently encountered 
(,2% of cumulative study patients experiencing a three-fold 
increase in transaminases or alkaline phosphatase above 
baseline) and comparable to other localized antifungal thera-
pies for oropharyngeal candidiasis (clotrimazole troches, 
nystatin suspension).14 A potential choking hazard exists 
for a drug with this formulation and mode of administration 
(obviating the appropriateness of use in young children), 
but specific events of this type have not been reported in the 
current literature.
Place in therapy
OPC can be effectively treated with topical or systemic 
antifungal therapy. There are distinct advantages and 
disadvantages to both types of treatment. The preferred 
treatment of OPC often differs by patient population, with 
systemic agents more often used in immunosuppressed 
patients than the topical options. There are several other 
factors that may also affect treatment choice including 
infection type and severity, presence of Candidal infection 
elsewhere (vulvovaginal, intertrigo), drug efficacy, adverse 
effects, ease and frequency of administration, anticipated 
adherence, gastric acidity (which may affect absorption), 
possible systemic toxicity, drug–drug interactions, and   
cost.
Oral fluconazole is first-line systemic therapy for OPC. 
Treatment with oral fluconazole 200 or 100 mg daily is easy 
and highly efficacious. A recent trial also suggests that a 
single dose of oral fluconazole 750 mg has equal efficacy and 
relapse rates.18 Itraconazole, voriconazole, and posaconazole 
also have efficacy in the treatment of OPC. However, these 
agents would typically only be used as salvage therapy in 
the setting of resistance or OPC with a non-albicans   Candida 
species.19,20 The Infectious Disease Society of America 
(IDSA) guidelines suggest itraconazole solution if flucon-
azole failure occurs. This strategy is effective 64%–80% of 
the time.21 Echinocandins may also be useful in this setting 
especially because they have a different mechanism of action 
than the azoles and may be used in cases of high-level azole 
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As noted previously, systemic therapy is most often used 
in patients who are significantly immune compromised. 
  Systemic therapy is also useful when there is concern that the 
infection extends past the oropharynx into the esophagus or 
elsewhere in the body, such as the skin folds or genitals. The 
major disadvantage of systemic therapy is the greater poten-
tial for drug–drug interactions, and systemic toxicity such 
as hepatotoxicity with systemic use. Though some degree of 
drug–drug interaction is noted with oral miconazole, systemic 
drug levels are typically undetectable.7 Though it has not been 
studied in a randomized manner, it is therefore likely that the 
incidence of systemic adverse effects would be less, as many 
of the adverse effects of azoles are level related.23
When comparing miconazole buccal tablets to the 
other topical agents, miconazole has the advantage of 
being applied once daily versus five times a day with 
clotrimazole troche and four times daily with nystatin 
swish and   swallow.24 Adherence has been shown to be 
greatly enhanced with less frequent dosing of all phar-
macological agents and this may therefore represent a 
potential advantage. The limited available adherence data, 
discussed previously, supports at least comparable rates for 
miconazole buccal tablets and alternative local therapies for 
oropharyngeal candidiasis but not clear superiority favor-
ing miconazole buccal tablets. At least one international 
organization has weighed in on the role of miconazole 
buccal tablets for the treatment of OPC. The World Health 
Organization (WHO) recently reviewed miconazole buc-
cal tablets for the treatment of OPC for inclusion on their 
WHO Model Lists of Essential Medicines. They determined 
that evidence for clinical benefits arising from a potential 
improved patient adherence was not available and rejected 
the proposal on the basis of inadequate comparison data 
with nystatin formulations.25
Because of the need for a suitable location to apply the 
adhesive tablet, miconazole buccal tablets may not be as 
useful as the other agents in denture-induced stomatitis. 
Angular cheilitis is best treated with topical antifungal creams 
or ointments.26
Cost considerations
Cost is an important consideration for the treatment of OPC 
due to the availability of generic or relatively low-cost treat-
ment options. The cost of oral miconazole buccal tablets for 
a 14-day treatment course is considerable (Table 1). As with 
many of the other OPC treatment options, we are unaware of 
any published pharmacoeconomic studies performed to date 
evaluating miconazole buccal tablets with less-expensive 
alternatives. In general, further cost-effectiveness studies 
for the treatment of OPC are needed due to the worldwide 
incidence of HIV and the potential financial impact on the 
global community.
Conclusion
Oropharyngeal candidiasis is a localized infection of the 
mucous membranes and is an especially common opportu-
nistic infection in patients with HIV . A variety of options, 
both systemic and topical, exist for the treatment of OPC. 
Miconazole buccal tablets are the most recent addition to 
the antifungal armamentarium available for the treatment 
of OPC. The convenient once-daily dosing may enhance 
patient adherence compared with existing topical options; 
however, the cost compared with both topical and systemic 
agents should be considered.
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